Avastin and Tarceva for Upper Gastrointestinal Cancers

Inclusion Criteria: * Histologically or cytologically verified carcinoma of the gall bladder or bile ducts. * PS 0-1 (ECOG scale) * Age \> 18 years * Life expectancy \> 3 months * Sufficient organ function, defined as: * Platelets \> 100 x 109/liter * Leukocytes \> 3,0 x 109/liter * ACN \> 1,5 x 109/liter * ASAT and/or ALAT \< 3 x upper normal limit * Bilirubin \< 1,5 x upper normal limit * EDTA clearance \> 45 ml/min * APTT and INR \< normal limit * Fertile females must use oral contraceptive, IUD (intrauterine device) or preservatives. Fertile males must use preservatives. Exclusion Criteria: * Radiotherapy or chemotherapy within the last 4 weeks * Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids * Any prior EGFR- or VEGFR-based therapy * Any condition (medical, social, psychological), which would prevent adequate information and follow-up * Tumor located close to major blood vessels and judged to possess a high risk of serious bleeding * Any other active malignancy, except basal or squamous cell carcinoma of the skin, or carcinoma in situ * Any significant cardiac disease (New York Heart Association Class II or greater), significant arrythmia, congestive heart failure, acute myocardial infarction within 6 months or unstable angina pectoris * Clinically significant peripheral vascular disease * Evidence of coagulopathy * Use of ASA, NSAIDs or clopidogrel * Major surgical procedure, open biopsy, …